Masand Prakash S, Culpepper Larry, Henderson David, Lee Scott, Littrell Kimberly, Newcomer John W, Rasgon Natalie
Department of Psychiatry, Duke University Medical Center, Durham, North Carolina, USA.
CNS Spectr. 2005 Oct;10(10):suppl14 1-15.
Patients with psychiatric disorders have an increased rate of cardiovascular morbidity and mortality compared with the general population. Metabolic issues such as weight gain, dyslipidemia, diabetes mellitus, diabetic ketoacidosis,and pancreatitis have been reported with the use of antipsychotic agents. Although atypical antipsychotics have not been linked directly to the development of metabolic syndrome, these medications have been shown to increase risk factors that can lead to metabolic and endocrine disturbances. Therefore, clinicians should provide ongoing monitoring for patients who are being treated for psychiatric disorders with these agents. According to the 2004 Consensus Report on Antipsychotics, screening measures should include baseline and follow-up monitoring of personal/family histories, weight (body mass index), waist circumference, blood pressure, fasting plasma glucose, and fasting lipid profile.
与普通人群相比，患有精神疾病的患者心血管疾病的发病率和死亡率更高。使用抗精神病药物已报告出现如体重增加、血脂异常、糖尿病、糖尿病酮症酸中毒和胰腺炎等代谢问题。虽然非典型抗精神病药物与代谢综合征的发生没有直接关联，但这些药物已被证明会增加导致代谢和内分泌紊乱的风险因素。因此，临床医生应对正在使用这些药物治疗精神疾病的患者进行持续监测。根据2004年抗精神病药物共识报告，筛查措施应包括对个人/家族病史、体重（体重指数）、腰围、血压、空腹血糖和空腹血脂谱进行基线和随访监测。
